Beth C. Seidenberg net worth and biography

Beth Seidenberg Biography and Net Worth

Director of Vera Therapeutics

Dr. Seidenberg is a founding managing director of Westlake Village BioPartners and a general partner at Kleiner Perkins, a leading venture capital firm. A longtime life sciences investor, she has incubated-invested 25 biotech ventures.

Dr. Seidenberg has a demonstrated ability to identify and accelerate medically meaningful molecules through development. Her expertise is grounded in her significant senior level industry experience with leadership roles at Amgen, Bristol-Myers Squibb and Merck Research Laboratories. Most recently, at Amgen, Dr. Seidenberg was chief medical officer and head of global development.

Dr. Seidenberg holds a Bachelor of Science degree in biology and anthropology from Barnard College and attended medical school at the University of Miami School of Medicine. She completed her medical residency at Johns Hopkins University and the George Washington University, and Fellowship at the National Institutes of Health.

What is Beth C. Seidenberg's net worth?: The estimated net worth of Beth C. Seidenberg is at least $2.80 million as of October 28th, 2024. Seidenberg owns 131,553 shares of Vera Therapeutics stock worth more than $2,800,763 as of April 17th. This net worth evaluation does not reflect any other assets that Seidenberg may own. Learn More about Beth C. Seidenberg's net worth.
How do I contact Beth C. Seidenberg?: The corporate mailing address for Seidenberg and other Vera Therapeutics executives is , , . Vera Therapeutics can also be reached via phone at 650-770-0077 and via email at ir@veratx.com. Learn More on Beth C. Seidenberg's contact information.
Has Beth C. Seidenberg been buying or selling shares of Vera Therapeutics?: Beth C. Seidenberg has not been actively trading shares of Vera Therapeutics during the past quarter. Most recently, Beth C. Seidenberg sold 15,000 shares of the business's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $48.03, for a transaction totalling $720,450.00. Following the completion of the sale, the director now directly owns 131,553 shares of the company's stock, valued at $6,318,490.59. Learn More on Beth C. Seidenberg's trading history.
Who are Vera Therapeutics' active insiders?: Vera Therapeutics' insider roster includes Marshall Fordyce (Founder), Marshall Fordyce (CEO and Founder), Sean Grant (CFO), Maha Katabi (Director), Beth Seidenberg (Director), and Joseph Young (CAO). Learn More on Vera Therapeutics' active insiders.
Are insiders buying or selling shares of Vera Therapeutics?: In the last year, insiders at the sold shares 10 times. They sold a total of 156,898 shares worth more than $6,681,787.73. The most recent insider tranaction occured on January, 8th when CEO Marshall Fordyce sold 17,500 shares worth more than $730,450.00. Insiders at Vera Therapeutics own 21.7% of the company. Learn More about insider trades at Vera Therapeutics.
Information on this page was last updated on 1/8/2025.

Beth C. Seidenberg Insider Trading History at Vera Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/28/2024	Sell	15,000	$48.03	$720,450.00	131,553
9/18/2024	Sell	1,177	$42.01	$49,445.77	160,376
3/30/2023	Buy	2,300	$7.24	$16,652.00	1,949,295
3/27/2023	Buy	1,633	$7.24	$11,822.92	1,923,087
3/24/2023	Buy	1,833	$7.24	$13,270.92	1,921,454
3/20/2023	Buy	15,252	$7.21	$109,966.92	1,919,621
3/17/2023	Buy	74,045	$7.12	$527,200.40	1,904,369
3/15/2023	Buy	32,844	$7.12	$233,849.28	1,770,227
3/10/2023	Buy	48,003	$7.16	$343,701.48	1,737,383
3/3/2023	Buy	1,000	$7.25	$7,250.00	1,689,380
3/1/2023	Buy	100	$7.25	$725.00	1,665,002
2/23/2023	Buy	200	$7.24	$1,448.00	1,664,902
2/13/2023	Buy	10,072	$7.20	$72,518.40	1,664,702
2/8/2023	Buy	45,357	$7.22	$327,477.54	1,654,230
2/3/2023	Buy	46,163	$7.24	$334,220.12	1,389,315

Beth C. Seidenberg Buying and Selling Activity at Vera Therapeutics

Vera Therapeutics Company Overview

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Today's Range

Now: $21.29

$20.98

$21.79

50 Day Range

MA: $26.64

$18.86

$35.88

2 Week Range

Now: $21.29

$18.53

$51.61

Volume

661,231 shs

Average Volume

751,774 shs

Market Capitalization

$1.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28